Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Wilson Website

Wyndham Wilson, M.D., Ph.D.

Selected Publications

1)  Wilson WH, Pittaluga S, Nicolae A, Camphausen K, Shovlin M, Steinberg SM, Roschewski M, Staudt LM, Jaffe ES, Dunleavy K.
A prospective study of mediastinal gray zone lymphoma.
Blood. [Epub ahead of print], 2014.
2)  Parilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL.
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.
Blood. [Epub ahead of print], 2014.
3)  Dunleavy K, Wilson WH.
Appropriate management of molecular subtypes of diffuse large B-cell lymphoma.
Oncology (Williston Park, N.Y.). 28: 326-34, 2014.
4)  Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho J, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A.
Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.
Haematologica. [Epub ahead of print], 2014.
5)  Roschewski M, Staudt LM, Wilson WH.
Diffuse large B-cell lymphoma-treatment approaches in the molecular era.
Nat Rev Clin Oncol. 11: 12-23, 2014.
6)  Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian J, Wilson WH, Van Etten RA.
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Leuk. Lymphoma. [Epub ahead of print], 2014.
7)  Roschewski M, Manasanch EE, Wilson WH.
Management of heavy chain diseases: the challenges of biologic heterogeneity.
Oncology. 28: 63-5, 2014.
8)  Roschewski M, Dunleavy K, Wilson WH.
Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.
Leuk. Lymphoma. [Epub ahead of print], 2014.
9)  Kawabata S, Mercado-Matos JR, Hollander MC, Donahue D, Wilson W, Regales L, Butaney M, Pao W, Wong KK, Jänne PA, Dennis PA.
Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.
Cell Rep. 7: 1824-32, 2014.
10)  Dogan I, Kawabata S, Bergbower E, Gills JJ, Ekmekci A, Wilson W, Rudin CM, Dennis PA.
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.
Lung Cancer. 85: 1-6, 2014.
Click Here to View Expanded Bibliography.

This page was last updated on 8/21/2014.